Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N,N-[2,5-O-dibenzyl-glucaryl]-DI-[valinyl-aminomethanyl-pyridine] is an experimental small molecule inhibitor, also known as INHIBITOR MSA367 and MS3. It is a synthetic compound classified as an amino acid derivative and peptide analog. The molecule features a glucaric acid core with dibenzyl protection at the 2 and 5 positions, linked via amide bonds to two valine-derived aminomethanyl-pyridine moieties. Its primary research use has been as a chemical inhibitor in structural biology studies; it has not been approved for clinical use or assigned any therapeutic indication. There are no reported clinical trials or marketed products containing this compound[1][6][8]. Its mechanism of action is not explicitly described in public sources, but it has been used in the context of HIV Gag-Pol polyprotein inhibition studies[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N,N-[2,5-O-dibenzyl-glucaryl]-DI-[valinyl-aminomethanyl-pyridine].